Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 60 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

60 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 60 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

60 programs

Clinical programs

Page 1 of 2

  1. 16995

    Regeneron UK Limited

    Neovascular Macular Degeneration

    approved small molecule completed

    1 trial

  2. 17508

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

  3. 17668

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  4. Aflibercept

    Regeneron UK Limited

    Submacular Vascularized Pigment Epithelial Detachments

    approved small molecule completed

    1 trial

  5. Aflibercept

    Regeneron UK Limited

    Exudative Macular Degeneration

    approved small molecule completed

    1 trial

  6. Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    2 trials

  7. Aflibercept

    Regeneron UK Limited

    Age Related Macular Degeneration

    approved small molecule active

    1 trial

  8. Aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  9. Aflibercept

    Regeneron UK Limited

    Retinal Vein Occlusion

    approved small molecule active

    2 trials

  10. Aflibercept

    Regeneron UK Limited

    Fibrovascular Pigment Epithelial Detachment

    approved small molecule terminated

    1 trial

  11. Aflibercept (2.0 mg)

    Regeneron UK Limited

    Macular Edema With Central Retinal Vein Occlusions

    approved small molecule completed

    1 trial

  12. Aflibercept (BAY86-5321, Eylea)

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    1 trial

  13. Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    approved small molecule active

    1 trial

  14. Aflibercept Injection

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  15. Aflibercept Ophthalmic

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  16. Alirocumab

    Regeneron UK Limited

    Myocardial Infarction

    approved small molecule terminated

    2 trials

  17. Alirocumab

    Regeneron UK Limited

    Atherosclerosis

    approved small molecule active

    1 trial

  18. Alirocumab

    Regeneron UK Limited

    Dyslipidemia

    approved small molecule completed

    1 trial

  19. Alirocumab 150 MG/ML subcutaneous injection

    Regeneron UK Limited

    Saphenous Vein Graft Atherosclerosis

    approved small molecule terminated

    1 trial

  20. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolemia

    approved small molecule completed

    1 trial

  21. Colchicine (Colcrys®)

    Regeneron UK Limited

    Intercritical Gout

    approved small molecule completed

    1 trial

  22. Dupilumab

    Regeneron UK Limited

    Eczema

    approved small molecule active

    1 trial

  23. Dupilumab

    Regeneron UK Limited

    Moderate-to-Severe Atopic Dermatitis

    approved small molecule completed

    2 trials

  24. Dupilumab

    Regeneron UK Limited

    Keloid

    approved small molecule completed

    2 trials

  25. Dupilumab

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial

  26. Dupilumab

    Regeneron UK Limited

    Dermal Hypersensitivity Reaction

    approved small molecule completed

    1 trial

  27. Dupilumab

    Regeneron UK Limited

    Dermatitis, Atopic

    approved small molecule active

    5 trials

  28. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis

    approved small molecule active

    4 trials

  29. Dupilumab

    Regeneron UK Limited

    Allergic Contact Dermatitis

    approved small molecule active

    1 trial

  30. Dupilumab

    Regeneron UK Limited

    Asthma

    approved small molecule active

    13 trials

  31. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    16 trials

  32. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis (AD)

    approved small molecule terminated

    2 trials

  33. Dupilumab

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  34. Dupilumab

    Regeneron UK Limited

    Eosinophilic Oesophagitis

    approved small molecule active

    1 trial

  35. Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    approved small molecule active

    1 trial

  36. Dupilumab Injectable Product

    Regeneron UK Limited

    Asthma

    approved small molecule active

    1 trial

  37. Dupilumab Only Product

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

  38. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Nasal Polyps

    approved small molecule active

    1 trial

  39. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial

  40. Dupilumab SAR231893

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule completed

    1 trial

  41. Dupilumab SAR231893

    Regeneron UK Limited

    Dermatitis Atopic

    approved small molecule completed

    2 trials

  42. Dupixent

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

  43. Intravitreal Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule terminated

    2 trials

  44. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Cystoid Macular Edema

    approved small molecule completed

    1 trial

  45. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Chorioretinal Vascular Disease

    approved small molecule completed

    1 trial

  46. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Age - Related Macular Degeneration (AMD)

    approved small molecule completed

    1 trial

  47. Intravitreal Aflibercept Injection 2mg

    Regeneron UK Limited

    Neovascular Age-related Macular Degeneration

    approved small molecule active

    2 trials

  48. Intravitreal aflibercept injection

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

60 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.